RT Journal Article
SR Electronic
T1 Objective quantitation of EGFR protein levels using Quantitative Dot Blot (QDB) method for prognosis of gastric cancer patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.12.21255321
DO 10.1101/2021.04.12.21255321
A1 Lei Xin
A1 Fangrong Tang
A1 Bo Song
A1 Maozhou Yang
A1 Jiandi Zhang
YR 2021
UL http://medrxiv.org/content/early/2021/04/15/2021.04.12.21255321.abstract
AB Background One causing factor underlying failures of several clinical trials of anti-EGFR therapies is the lack of effective method to select patients overexpressing EGFR protein. Quantitative Dot Blot method (QDB) is proposed here to measure EGFR protein levels objectively and quantitatively. Its feasibility was evaluated for prognosis of overall survival (OS) of gastric cancer patients.Methods Formalin Fixed Paraffin Embedded (FFPE) slices of 2×5 μm from gastric and Lung cancer specimens were used to extract total tissue lysate for QDB measurement. Absolutely quantitated EGFR protein levels were used for Kaplan-Meier Overall Survival (OS) analysis of gastric cancer patients.Results EGFR protein levels ranged from 0 to 772 pmole/g (n=246) for gastric, and from 0 to 2695 pmole/g (n=81) for lung cancer patients. Poor correlation was observed between quantitated EGFR levels and immunohistochemistry (IHC) scores with r=0.018, p=0.786 from Spearman’s correlation analysis. EGFR was identified as an independent negative prognostic biomarker for gastric patients only through absolute quantitation, with HR at 2.29 (95%CI:1.23-4.26, p=0.0089) from multivariate cox regression OS analysis. A cutoff of 207.7 pmole/g was proposed to stratify gastric cancer patients, with 5-year survival probability at 37% for those whose EGFR levels were above the cutoff, and at 64% those below the cutoff based on Kaplan-Meier OS analysis. p=0.0057 from Log Rank test.Conclusion A QDB-based assay was developed for both gastric and Lung cancer specimens to measure EGFR protein levels absolutely, quantitatively and objectively. This assay should facilitate clinical trials aiming to evaluate anti-EGFR therapies retrospectively and prospectively.Competing Interest StatementFT, MY & JZ are employees of Yantai Quanticision Diagnostics, Inc., a division of Quanticision Diagnostics Inc. who hold patents US9933418, US10295544, & US10788484 covering QDB method and its applications in clinical diagnostics. LX & BS declared no conflict of interest. Funding StatementThe project was funded by Quanticision Diagnostics, Inc. at RTP, NC, USAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the Declaration of Helsinki, following a protocol approved by ethics committee of Yantaishan hospital (YanshanLunZhun2021017 to Lei Xin), with an informed consent waiver due to the use of archival tissues with retrospective, anonymized clinical data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the correspondent author upon reasonable written request.